Skip to main navigation Skip to search Skip to main content

Multi-omics–based machine learning model predicts response and guides treatment in Crohn disease: a case study in nutritional therapy

  • Asaf Azulay
  • , Leora Gotesdyner
  • , Yonat Aharoni-Frutkoff
  • , Gili Focht
  • , Yael Talmor
  • , Elhanan Borenstein
  • , Luba Plotkin
  • , Esther Orlanski-Meyer
  • , Raffi Lev-Tzion
  • , Oren Ledder
  • , Dotan Yogev
  • , Amit Assa
  • , Efrat Broide
  • , Anat Yerushalmy-Feler
  • , Jarosław Kierkuś
  • , Tobias Schwerd
  • , Eytan Wine
  • , Dan Turner*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: Biomarkers are needed to predict treatment response and guide therapeutic decisions in Crohn disease (CD). We aimed to develop and validate a multi-omics machine learning (ML) model to predict response to nutritional therapy in pediatric CD. Methods: Treatment-naive children with newly diagnosed CD who were initiating exclusive enteral nutrition (EEN) were prospectively enrolled in this study. Metabolomics and lipidomics were measured in the serum and stool, as well as the fecal microbiome. Following feature selection via minimum redundancy maximum relevance, random-forest models were constructed for single- and multi-omics and performances were evaluated. The models were externally validated in an independent prospective cohort of treatment-naive children and young adults with CD treated with EEN. Results: The discovery cohort consisted of 50 children (mean ± SD age 14.3 ± 2.7 years), of whom 34 (68%) responded to EEN. Combining complementary signals from host metabolism, gut microbiota, and lipid profiles from serum and stool in a multi-omics ML model yielded a model for predicting treatment response (training accuracy 94%; 95% CI, 82%-100%). Key predictive features included serum metabolites (2-hydroxyglutaric acid, Cer[d18:0/22:0], and HexCer[d18:1/d26:1]), fecal metabolites (3-methyladipic acid, DG[16:0 20:0], PC aa C42:2), and microbial taxa (family Bifidobacteriaceae and genus CAG-56). The validation cohort consisted of 21 patients of whom 12 (57%) responded to EEN. The multi-omics model performance achieved an area under the receiver operating characteristic curve (AUROC) of 0.81 (95% CI, 0.6-1.0). Clinical and endoscopic features did not improve the predictive ability of the model. Conclusion: As a proof-of-concept, we showed that integrated multi-omics ML models can predict EEN response in pediatric CD patients, supporting their potential use in precision nutrition and personalized care strategies.

Original languageEnglish
Pages (from-to)1513-1523
Number of pages11
JournalInflammatory Bowel Diseases
Volume32
Issue number8
DOIs
StatePublished - Aug 2026

Bibliographical note

Publisher Copyright:
© The Author(s) 2026. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected]. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)

Keywords

  • Children
  • Crohn disease
  • Exclusive enteral nutrition
  • Metabolomics
  • Microbiome
  • Multiomics
  • Nutritional therapy
  • Prediction

Fingerprint

Dive into the research topics of 'Multi-omics–based machine learning model predicts response and guides treatment in Crohn disease: a case study in nutritional therapy'. Together they form a unique fingerprint.

Cite this